uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial

Wednesday, January 6, 2016 9:15 PM UTC

AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.

The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the "Events" section on the "Media" page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.

Conference Call Numbers

London, United Kingdom:		+44 (0) 20 3427 1906
New York, United States of America:		+1 212 444 0412
Berlin, Germany:		+49 (0) 30 3001 90534
Amsterdam, Netherlands:		+31 (0) 20 716 8296
Paris, France:		+33 (0) 1 76 77 22 31
Milan, Italy:		+39 02 3859 1420
Brussels, Belgium:		+32 (0) 2 402 3092
Montreal, Canada:		+1 514 841 2154

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

CONTACT: uniQure:
         Direct: +31 20 240 6110
         Main: +31 20 240 6000
         [email protected]
         
         Media inquiries:
         Gretchen Schweitzer
         MacDougall Biomedical Communications
         Direct: +49 172 861 8540
         Main: +49 89 2424 3494 or
         +1 781 235 3060
         [email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial

Editor's Picks

Welcome to EconoTimes